LCI-GU-URO-CRI-001: A Phase II Study of Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer
Phase of Trial: Phase II
Latest Information Update: 17 Aug 2017
At a glance
- Drugs Crizotinib (Primary)
- Indications Urogenital cancer
- Focus Therapeutic Use
- 11 Aug 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 11 Aug 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 16 Feb 2016 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov record.